A comparison of the aldosterone-blocking agents eplerenone and spironolactone

Clinical Cardiology

Volumn 32, Issue 4, 2009, Pages 230-

  Karagiannis, Asterios ^a,b   Athyros, Vasilios G ^a,b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPLERENONE; POTASSIUM; SPIRONOLACTONE;

DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; GYNECOMASTIA; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; LETTER; MONOTHERAPY; PATIENT COMPLIANCE; POTASSIUM BLOOD LEVEL;

ALDOSTERONE ANTAGONISTS; HEART FAILURE; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPIRONOLACTONE;

EID: 64849100574     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20442     Document Type: Letter

References (3)

1. Struthers A, Krum H, Williams GH. A comparison of the aldosteroneblocking agents eplerenone and spironolactone. Clin Cardiol. 2008; 31:153-158.
2. Karagiannis A, Tziomalos K, Papageorgiou A, Kakafika AI, Pagourelias ED, et al. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother. 2008;9:509-515.
3. Menard J. The 45-year story of the development of an antialdosterone more specific than spironolactone. Mol Cell Endocrinol. 2004;217:45-52.